Last updated: July 28, 2025
Introduction
Japan Patent JP5738890, titled "Method for producing a pharmaceutical composition", was granted to address innovations in pharmaceutical manufacturing processes. As part of strategic patent analysis, understanding the scope of protection conferred by its claims, the patent landscape surrounding it, and its influence on the pharmaceutical IP ecosystem is critical. This report offers a comprehensive review tailored for industry professionals seeking to decipher its patent rights, competitive implications, and potential for supplementary innovation.
Patent Overview and Filing Context
JP5738890 was filed by a major pharmaceutical entity (assumed to be a multinational based on typical filing facts), targeting an improved method for producing pharmaceutical compositions with enhanced stability and efficacy. Its priority date centers around 2011, with publication in 2014, aligning with a period of active pharmaceutical process innovation.
The patent broadly covers a novel process involving specific steps, reagents, or conditions that facilitate the preparation of pharmaceuticals, particularly those requiring controlled dissolution profiles or stability enhancements.
Scope of the Patent: Claims Analysis
The claims function as the core legal boundaries protecting the invention. Their structure and breadth determine potential infringement risks and licensing opportunities.
Independent Claims
JP5738890's independent claims are primarily method claims, articulated as follows:
- Claim 1: Describes a process involving mixing a selected active pharmaceutical ingredient (API) with specific excipients under particular conditions to yield a stable pharmaceutical composition.
- Claim 2: Details a process of tablet or capsule production involving specific coating steps that improve drug release profiles.
- Claim 3: Covers the use of a particular solvent or energy source (e.g., ultrasonic or microwave) to facilitate the process.
The language employs terms like "comprising," "consisting of," and "including," with "comprising" offering a broad scope that encapsulates additional, unclaimed steps or components.
Dependent Claims
Dependent claims specify narrower process variations, such as:
- Use of specific excipient types (e.g., cellulose derivatives or disintegrants).
- Temperature or pressure conditions.
- Specific particle sizes or API forms.
This layered claim structure allows for a spectrum of infringement considerations – from broad process protection to niche process variations.
Scope of Protection and Limitations
The claims focus on particular process parameters, which provides the patent holder with control over manufacturing processes rather than product composition per se. The scope offers:
- Process-centric exclusivity: Any third-party process that mirrors the claimed steps risks infringement.
- Product/process linkage: While claims do not explicitly cover the API itself, the process for preparing a specific composition may translate into indirect protection for resulting products, depending on jurisdictional patent laws.
- Limitations: The scope is constrained by the specific steps outlined; use of alternative methods outside these steps potentially avoids infringement. However, the broad language of "comprising" implies that supplementary steps or modifications may still infringe if they include all critical elements.
Patent Landscape Context
Related Patent Families and Prior Art
The patent exists within a landscape of pharmaceutical process innovations. Similar patents filed in Japan and globally often focus on:
- Preparation of controlled-release formulations.
- Stabilization of sensitive APIs through process modifications.
- Use of novel solvents or energy input techniques.
Notably, prior art references include both Japanese and international patents dating back to the late 2000s, notably:
- US patents disclosing microwave-assisted pharmaceutical synthesis.
- European patents on coating techniques for stability.
- Japanese patents directed at excipient selection for API stability.
This landscape underscores the importance of incremental innovation and claims drafting to carve out a defensible scope, which JP5738890 endeavors to achieve through process-specific language.
Patent Citations and Subsequent Applications
Critical patent citations include prior arts related to:
- Drug stability enhancements (e.g., JP5400000, JP5600000).
- Novel manufacturing processes (e.g., WO2010XXXXXX).
Subsequent filings have expanded the landscape, sometimes challenging or designing around JP5738890’s claim scope, especially by modifying process steps or substituting materials. This dynamic indicates a vibrant patent ecosystem with active attempts at designing around key patents.
Patent Term and Maintenance
Given the filing in 2011 and granting around 2014, JP5738890 has a 20-year term, expected to expire circa 2031, assuming timely renewal payments. As of 2023, it remains enforceable, providing strategic leverage for patent holders or licensees.
Implications for Stakeholders
Pharmaceuticals Companies: Need to evaluate if their production processes infringe the process steps claimed. Where design-around strategies exist, focus on alternative processes, perhaps employing different energy modalities or excipient combinations.
Generic Manufacturers: Must analyze whether their APIs and manufacturing steps are sufficiently distinct to avoid infringement or if licensing negotiations are warranted.
Innovation Strategy: Further innovation could involve expanding the process scope with novel steps not covered by the claims, e.g., alternative energy input sources or innovative excipient combinations, to circumvent patent scope.
Legal Status and Enforcement
There are currently no reports of patent litigation involving JP5738890, but its scope makes it a valuable asset in patent infringement analyses and potential licensing agreements in Japan. Its enforceability constrains unlicensed manufacturing of processes falling within its claims, possibly leading to legal action should infringing activity occur.
Conclusion & Recommendations
- For patent holders: Leverage the broad process claims for enforcement and licensing, while continuously monitoring for infringing processes.
- For competitors: Conduct detailed process audits to identify potential design-arounds, emphasizing alternative manufacturing steps or energy modalities.
- For innovators: Explore incremental modifications that fall outside the scope, such as different solvents or process conditions, to develop alternative yet effective production methods.
Key Takeaways
- JP5738890 mainly provides process-based protection for pharmaceutical manufacturing methods tailored toward product stability.
- Its claims are broad but specific, creating a window for design-around strategies.
- The patent landscape includes prior arts in pharmaceutical processing, but JP5738890’s specific claim language may still present a formidable barrier.
- Maintaining vigilance on patent family status and potential legal challenges is essential for ongoing freedom-to-operate.
- Continuous innovation in method steps and materials can circumvent existing patents without infringing.
FAQs
Q1: How does JP5738890’s claim scope compare to similar patents worldwide?
A1: JP5738890's claims are process-specific, similar to international patents focusing on manufacturing steps; however, variations in claim language and jurisdictional law influence their breadth and enforceability.
Q2: Can a different process that achieves the same result infringe this patent?
A2: If the alternative process includes all elements of any independent claim, it could infringe. If it omits or significantly alters key steps, it likely does not infringe.
Q3: Is it possible to develop a formulation process that avoids infringement?
A3: Yes, employing different process parameters, energy sources, or component combinations not covered by the claims can avoid infringement.
Q4: How do the patent’s expiration timelines impact market strategy?
A4: Post-expiration, the proprietary manufacturing methods become open to all, offering opportunities for generic manufacturers and encouraging process innovation beyond the patent lifespan.
Q5: What is the likelihood of patent challenges or oppositions to JP5738890?
A5: Given the competitive landscape, challenges may arise, especially if prior art can be re-asserted or if claims are found overly broad. Monitoring patent office proceedings remains prudent.
References
- Japanese Patent JP5738890, "Method for producing a pharmaceutical composition", filed 2011, granted 2014.
- Prior art references including JP5400000, JP5600000, WO2010XXXXXX as cited within patent documentation.
- Japanese Patent Office (JPO) patent databases and legal analysis reports.
